Description: VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
Home Page: www.vita34.de
Deutscher Platz 5a
Leipzig,
04103
Germany
Phone:
49 341 48792 40
Officers
| Name | Title |
|---|---|
| Mr. Jakub Julian Baran | Chairman of the Management Board & CEO |
| Mr. Tomasz Franciszek Baran | VP of the Management Board & Chief Commercial Officer |
| Mr. Dirk Plaga | CFO & Member of Management Board |
| Santiago Luengo | Managing Director of Secuvita |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5937 |
| Price-to-Sales TTM: | 2.0631 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 775 |